Skip to main content

Table 1 Patient characteristics of study population

From: Kidney REPLACEment therapies in patients with acute kidney injury and RHABDOmyolysis (ReplaceRhabdo): a pilot trial

Parameter

All n = 15

CVVH n = 5

CVVHD-HCO n = 5

CVVHD-CS n = 5

p

General characteristics:

 Age (years)

68 [62; 77]

62 [47; 72]

74 [66; 77]

75 [61; 81]

0.223

 Sex (male) n, (%)

12 (80.0)

5 (100.0)

4 (80.0)

3 (60.0)

0.287

 High (cm)

175 [169; 180]

180 [175; 182]

175 [167; 180]

172 [160; 178]

0.200

 Weight (kg)

94 [82; 108]

102 [91; 150]

94 [80; 104]

82 [72; 96]

0.129

 BMI (kg/m2)

31.6 [26.8; 34.5]

34,5 [28.4; 45.3]

32.2 [27.0; 33.0]

27.7 [25.2; 33.4]

0.289

 Mechanical ventilation n, (%)

9 (60)

4 (80)

2 (40)

3 (60)

0.435

 Sepsis n, (%)

7 (47)

2 (40)

3 (60)

2 (40)

0.765

 Vasopressors n, (%)

10 (67)

4 (80)

3 (60)

3 (60)

0.741

 AKI 3 n, (%)

13 (87)

4 (80)

4 (80)

5 (100)

0.562

 SOFA

13 [11; 15]

12 [10; 17]

12 [10; 14]

14 [12; 16]

0.586

 APACHE II

31 [28; 39]

29 [28; 39]

30 [29; 35]

42 [30; 44]

0.277

 MAP (mmHg)

65 [61; 72]

65 [59; 76]

65 [61; 74]

62 [59; 68]

0.618

 24-h diuresis (ml)a

180 [68; 433]

215 [43; 508]

100 [45; 455]

260 [45; 570]

0.997

Comorbidities:

 • Chronic heart failure (NYHA IV) n, (%)

0 (0)

0 (0)

0 (0)

0 (0)

 

 • Pre-existing immunosuppression n, (%)

1 (7)

1 (20)

0 (0)

0 (0)

0.343

 • Liver cirrhosis n, (%)

1 (7)

1 (20)

0 (0)

0 (0)

0.343

 • Active malignancy n, (%)

2 (13)

1 (20)

0 (0)

1 (20)

0.562

 • Chronic pulmonary disease n, (%)

0 (0)

0 (0)

0 (0)

0 (0)

 

 • eGFR < 45 ml/min/1.73m2 n, (%)

2 (13)

1 (20)

1 (20)

0 (0)

0.562

Causes of rhabdomyolysis:

 • Muscle hypoxia n, (%)

6 (40)

1 (20)

2 (40)

3 (60)

 

 • Drugs and toxins n, (%)

1 (7)

1 (20)

0 (0)

0 (0)

 

 • Shock and post CPR n, (%)

8 (53)

3 (60)

3(60)

2 (40)

0.517

Indications for KRT:

 • Acidosis (pH < 7,25) n, (%)

6 (40)

2 (40)

3 (60)

1 (20)

0.435

 • High potassium level (> 6 mmol/l) n, (%)

2 (13)

2 (40)

0 (0)

0 (0)

0.099

 • Pulmonary edema n, (%)

6 (40)

2 (40)

2 (40)

2 (40)

1.000

 • Uremia (urea > 25 mmol/l) n, (%)

6 (40)

2 (40)

3 (60)

1 (20)

0.435

 • Oliguria/Anuria n, (%)

11 (73)

3 (60)

5 (100)

3 (60)

0.256

  1. Data presented as n (%) or median [25th, 75th quantile]
  2. AKI acute kidney injury, APACHE II Acute Physiology And Chronic Health Evaluation II, BMI body mass index, CPR cardiopulmonary resuscitation, CytoSorb®, CVVH continuous veno-venous hemofiltration, CVVHD continuous veno-venous hemodialysis, GFR glomerular filtration rate, HCO high cut-off, HR heart rate, KRT kidney replacement therapy, MAP mean arterial pressure, NYHA New York Heart Association, SOFA sequential organ failure assessment
  3. a24-h-diuresis before initiation of KRT
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us